What Is the Life Expectancy for Normal Pressure Hydrocephalus?

People diagnosed with normal pressure hydrocephalus (NPH) face a shortened life expectancy compared to the general population, but how much shorter depends heavily on whether they receive treatment. A meta-analysis covering more than 1,600 shunted NPH patients found their risk of death was roughly 80 percent higher than that of age-matched controls, though much of that excess risk reflects the advanced age and burden of other diseases typical of the NPH population rather than hydrocephalus alone.¹ One large study of shunted patients reported a median survival of about seven to eight years after surgery, with women living longer than men. The picture for untreated NPH is considerably grimmer, and the gap between treated and untreated outcomes is one of the most important things to understand about this condition.

How Shunt Surgery Changes Survival

The single biggest factor separating better and worse outcomes in NPH is whether a person undergoes shunt surgery. A study of U.S. veterans found that shunted patients did not have a statistically significant difference in overall survival compared to matched controls, while non-shunted patients had roughly 82 percent higher mortality than controls.² That finding is striking: it suggests that for properly selected patients, shunting can bring survival close to what you’d expect for someone of the same age without NPH.

A Japanese study of 200 shunted patients (average age at surgery around 78) found the median overall survival was 7.7 years. Women fared better, with a median survival of 8.8 years compared to 5.9 years for men.³ During follow-up, about half the patients died, with the most common causes of death being general frailty and senility, pneumonia, and cancer. Those causes are the same ones that dominate mortality statistics for any group of people in their late 70s and 80s, which reinforces the idea that shunting shifts the cause-of-death profile away from hydrocephalus-specific problems and back toward ordinary age-related conditions.

Still, “close to normal” is not the same as “normal.” The large meta-analysis that pooled data from multiple countries found a hazard ratio of 1.79 for shunted NPH patients compared to the general population, meaning a meaningfully elevated risk persists even after treatment.¹ Some of that gap likely reflects the fact that many NPH patients carry additional diagnoses that shorten life on their own.

What Happens Without Treatment

Untreated NPH carries a far worse prognosis. A population-based study that followed people with probable idiopathic NPH who had not undergone shunt surgery found that five-year mortality was 87.5 percent. The hazard ratio for death compared to those without NPH was 3.8, and those with milder forms of the condition still faced a substantially elevated risk of developing dementia.⁴ In other words, untreated NPH roughly quadrupled the risk of death over that window, and even people with less severe ventricular enlargement were not in the clear.

The reason for these numbers is that the hallmark symptoms of NPH, especially gait instability and cognitive decline, create a cascade of secondary problems. Falls are a major contributor to disability and death. A study examining 10-year mortality in NPH found that the risk of dying from cardiovascular disease, falls, and neurological conditions was significantly higher than in the general population. Cardiovascular disease was the leading cause of death, but falls were disproportionately represented, and most fall-related deaths involved subdural hematomas from head trauma.⁵ The combination of impaired balance, cognitive fog, and urinary urgency makes someone much more likely to fall, and because NPH patients are typically elderly, a fall can be catastrophic.

Why Comorbidities Drive So Much of the Mortality Picture

NPH is overwhelmingly a disease of older adults. Prevalence rises steeply with age, from around 0.2 percent of people aged 70 to 79 to nearly 6 percent of those 80 and older.⁶ That means almost everyone with NPH also has the cardiovascular disease, diabetes, kidney problems, and other conditions that accumulate in the eighth and ninth decades of life. These comorbidities don’t just coexist with NPH; they interact with it in ways that affect both treatment decisions and survival.

Vascular risk factors are especially predictive. Researchers who applied standard cardiovascular risk-scoring tools to NPH patients found that higher vascular risk scores were consistently associated with greater 10-year mortality. Each additional point on one widely used risk scale corresponded to a measurable increase in the chance of dying within a decade.⁷ This is useful because it means clinicians can use tools they already have to estimate how long a given NPH patient is likely to survive, which feeds into the risk-benefit calculation for shunt surgery.

One long-term follow-up study found that 37 percent of patients initially evaluated for NPH were lost to the five-year follow-up because they died from causes unrelated to hydrocephalus or their general health had deteriorated too far.⁸ The lesson is that NPH life expectancy cannot be understood in isolation. A person’s overall health, especially their cardiovascular status, often matters more than the hydrocephalus itself.

How Age Affects Shunt Outcomes

A common concern among patients and families is whether someone is “too old” for shunt surgery. The evidence is mixed but generally more optimistic than many people assume. A prospective study of 151 patients found that improvement after shunt surgery was independent of age up to the ninth decade, as long as patients had been properly selected through preoperative testing.⁹ The Japanese study mentioned earlier also found that patients over 80 had survival times and functional maintenance periods similar to those under 80 after shunting.³

However, another long-term study complicated this picture by finding that 64 percent of patients younger than 75 improved after shunting, while only 11 percent of those older than 75 improved.⁸ The difference may come down to patient selection. When preoperative testing, particularly a lumbar drainage trial, is used to confirm that someone’s symptoms genuinely respond to cerebrospinal fluid removal, older patients seem to do about as well as younger ones. When selection criteria are less strict, older patients do worse, probably because more of them have overlapping neurodegenerative conditions that shunting cannot fix.

Shunt Complications and Their Impact

Shunt surgery is not without risks, and some complications can themselves affect survival. Overdrainage, where too much cerebrospinal fluid is removed, is the most common category of complication. In one prospective study, overdrainage symptoms affected about a quarter of shunted patients, with 7 percent developing subdural fluid collections.¹⁰ Subdural hematomas are a recognized risk of shunting in NPH patients and can be life-threatening if they grow large enough to require surgical evacuation.¹¹

Shunt malfunction is the other major concern. Shunts can become blocked, disconnected, or infected, requiring revision surgery. Newer techniques are reducing some of these risks. Electromagnetic navigation during shunt placement has been shown to cut the rate of shunt malfunction dramatically over two-year follow-up compared to traditional freehand placement.¹² Programmable valves, which allow the flow rate to be adjusted noninvasively after surgery, have also become standard in many centers and help manage overdrainage without requiring additional operations.

For patients who cannot tolerate or are not good candidates for traditional shunting, endoscopic third ventriculostomy (ETV) is sometimes considered. This procedure creates a small opening in the floor of the brain’s third ventricle to reroute cerebrospinal fluid. A small study of 24 NPH patients who underwent ETV found that about 83 percent did not require subsequent shunt placement, though the remaining patients did eventually need a shunt.¹³ ETV is not as well studied as shunting for NPH, and most specialists still consider shunting the standard treatment.

The Diagnostic Delay Problem

One of the most frustrating aspects of NPH is how often it goes undiagnosed or is misdiagnosed as another condition. The classic symptom triad of gait disturbance, cognitive decline, and urinary incontinence overlaps heavily with Parkinson’s disease, Alzheimer’s disease, vascular dementia, and simple age-related decline. NPH has no distinct blood test or biomarker that allows a quick diagnosis, and identifying it requires piecing together clinical signs with brain imaging findings.¹⁴

This matters for life expectancy because delayed treatment means prolonged exposure to the risks of untreated NPH, especially falls and progressive cognitive deterioration. Population screening studies have found that NPH prevalence among people over 80 may be as high as 6 to 9 percent depending on the diagnostic criteria used, yet only a small fraction of those people receive treatment.⁶¹⁵ Some researchers believe NPH is one of the most underdiagnosed treatable causes of dementia in older adults. Every year that someone with NPH walks around with an incorrect Alzheimer’s or Parkinson’s diagnosis is a year of potential shunt benefit lost.

When NPH Overlaps with Alzheimer’s Disease

The relationship between NPH and Alzheimer’s disease complicates both diagnosis and prognosis. The two conditions share clinical features, particularly memory problems and difficulty with daily activities, and they can coexist in the same person. When they do, the effectiveness of shunt surgery tends to be reduced because the Alzheimer’s component of the cognitive decline will not respond to cerebrospinal fluid drainage.¹⁶

Cerebrospinal fluid biomarkers are increasingly being used to tease the two apart and to predict who will benefit from shunting. Patients with higher levels of neurofilament light chain (NfL) and total tau in their spinal fluid before surgery tend to improve less after shunting.¹⁷ Another study found that lower levels of these same markers, along with certain amyloid proteins, individually predicted long-term gait improvement after surgery, and a model combining several biomarkers with imaging data improved prediction further.¹⁸ In practical terms, someone whose spinal fluid shows heavy markers of neurodegeneration is less likely to have a good shunt response and may have a shorter life expectancy regardless of what is done surgically.

Predicting Who Will Do Well After Surgery

Because shunt surgery carries real risks, and because NPH patients are elderly, predicting who will benefit is critical. The strongest predictor remains a simple one: does draining cerebrospinal fluid temporarily improve the person’s symptoms? A large lumbar drainage test, where fluid is slowly removed over a day or two, followed by gait testing, has been shown to predict shunt success with over 90 percent accuracy.⁹

Brain imaging also plays a role. The DESH score, which measures a specific pattern on MRI where the brain’s ventricles are enlarged but the fluid spaces over the top of the brain are tight, has been validated as a predictor of shunt response. Patients with higher DESH scores are more likely to improve after surgery.¹⁹ Conversely, patients who showed no improvement after surgery tended to have lower DESH scores and worse baseline cognitive performance.²⁰

The clinical criteria for deciding to operate should bring together imaging findings, cerebrospinal fluid dynamics testing, and the results of drainage trials.²¹ When all of these point in the same direction, the odds of a good outcome are high. When the picture is ambiguous, clinicians have to weigh the surgical risks against the progressive decline that comes with leaving NPH untreated.

The Functional Window After Shunting

Survival alone does not tell the whole story. For many NPH patients and their families, the more pressing question is how long the person will remain functional and independent. Even among shunted patients who survive for years, daily function tends to decline over time. In the Japanese cohort, the median period of maintained daily activities was 2.6 years after surgery, regardless of sex. After that point, most patients experienced declining independence, most commonly from progressive frailty, pneumonia, or stroke.³

Gait tends to be the symptom that responds best and longest to shunting. At five years after surgery, patients still showed about a 40 percent improvement in walking ability and reaction time compared to their preoperative state. Cognitive improvement, however, was much harder to sustain, with fewer than 10 percent of patients showing lasting improvement on formal cognitive testing.⁸ This is one reason why early diagnosis matters so much. If you wait until cognitive decline is severe, shunting may restore some walking ability but leave the dementia largely unchanged. Patients treated while their cognitive symptoms are still mild tend to get more out of the procedure overall.

Falls, Cardiovascular Risk, and Specific Threats

Falls deserve particular emphasis because they are both a symptom and a major driver of poor outcomes. NPH patients who have fallen in the preceding six months tend to be older and more impaired across all symptom domains than those who have not.²² Falls in this population often lead to subdural hematomas, which are already more common in NPH patients because of the enlarged ventricular spaces and stretched bridging veins in their brains. A fall that might produce nothing more than a bruise in a younger person can trigger life-threatening bleeding.

Cardiovascular disease is the other major killer. As the 10-year mortality study showed, cardiovascular deaths were twice as common among NPH patients as in controls, accounting for 14 percent of all deaths compared to 7 percent in the matched general population.⁵ Whether this reflects a shared underlying vascular pathology or simply the demographic overlap between NPH and cardiovascular risk factors is still debated. Either way, aggressive management of blood pressure, cholesterol, and other cardiovascular risks is likely to have as much impact on life expectancy in NPH as the shunt itself.

The Caregiver Side

NPH does not affect only the patient. Caring for someone with gait instability, incontinence, and cognitive decline is physically and emotionally exhausting, and the caregiver burden associated with NPH is substantial. A study from the SINPHONI trial found that shunt surgery significantly reduced caregiver burden, with improvement in cognitive symptoms being the biggest driver of that relief.²³ One dimension of burden that did not improve, however, was the personal strain factor, the emotional toll on the caregiver. This suggests that even when the patient gets better objectively, the anxiety and disruption of having a loved one with a progressive neurological condition persist.

This has practical implications for planning. Families dealing with NPH should expect that even a successful shunt will not restore full independence indefinitely. The functional gains from surgery typically last a few years, after which the person’s overall frailty catches up. Building in long-term support structures early, rather than assuming the shunt solves everything, leads to better outcomes for both the patient and the family.